Table 1.

Clinical characteristics of patients enrolled in the 03-311 and BrUOG 211B trials and for whom gene expression data was available

DFCI 03-311, Number of patients (% of cohort)BrUOG 211B, Number of patients (% of cohort)
Clinical characteristicsTotal patients (N = 81)Gene expression data available (N = 72)Total patients (N = 60)Gene expression data available (N = 41)
Receptor statusER+ and/or PR+34 (42%)31 (43%)32 (53%)25 (61%)
ER− and PR−47 (58%)41 (57%)28 (47%)16 (39%)
Clinical stageIIA26 (32%)22 (30%)20 (33%)15 (37%)
IIB28 (35%)24 (33%)19 (32%)15 (37%)
IIIA16 (20%)15 (21%)11 (18%)6 (15%)
IIIB5 (6%)5 (7%)7 (12%)3 (7%)
IIIC3 (4%)3 (4%)3 (5%)2 (4%)
Tumor sizeT0/T13 (4%)2 (3%)5 (8%)3 (7%)
T246 (57%)40 (56%)36 (60%)27 (66%)
T324 (30%)22 (31%)11 (18%)8 (20%)
T46 (7%)6 (8%)8 (13%)3 (7%)
AgeMean (SD)48 (10.7)47 (9.7)52 (9.1)52 (9.0)